Immediate and long-term consequences of coronavirus disease 2019 on fertility and androgenic status of men
- Authors: Ignashov Y.A.1, Borovets S.Y.1, Rybalov M.A.1, Potapova M.K.1, Al-Shukri S.K.1
-
Affiliations:
- Academician I.P. Pavlov First St. Petersburg State Medical University
- Issue: Vol 14, No 3 (2024)
- Pages: 255-262
- Section: Original study
- Submitted: 23.05.2024
- Accepted: 08.09.2024
- Published: 17.11.2024
- URL: https://journals.eco-vector.com/uroved/article/view/632526
- DOI: https://doi.org/10.17816/uroved632526
- ID: 632526
Cite item
Abstract
BACKGROUND: The new coronavirus disease 2019 (COVID-19) recognized as a global pandemic, impacts many human organs and systems. In view of the coronavirus widespread and high incidence of the disease in young men of reproductive potential, It would be relevant to assess the immediate and long-term consequences of coronavirus disease on the reproductive system of men and their hormonal status
AIM: To study of the effect of COVID-19 on the male reproductive system and hormonal status.
MATERIALS AND METHODS: The study included the findings of examination and treatment of 62 men aged 22 to 45 years (mean age: 38.3 ± 3.2 years) who had COVID-19 confirmed by PCR testing within 3-6 months prior to the study. Sixteen (25.8%) men had severe disease, and 46 (74.2%) men suffered from moderate one. All patients enrolled in the study had spermogram parameters, mixed antiglobulin reaction (MAR) test findings and total plasma testosterone levels were within the reference values before the disease. These parameters were determined for all patients after recovery at 6 and 12 months.
RESULTS: Six months after the disease, significant spermatogenesis disorders, manifested by a decreasing concentration and/or mobility and/or the number of normal forms of spermatozoa, leukospermia, were observed in 14 of 16 (87.5%) patients in the severe disease group and in 16 of 46 (34.7%) patients with moderate severity disease (p < 0.05). Total plasma testosterone levels were decreased in all 16 (100%) patients in the severe group and in 32 of 46 (69.6%) patients in the moderate group (p < 0.05). Within 12 months after the disease, significant disorders in the main spermogram parameters were observed in 5 of 16 (31.2%) patients with severe coronavirus disease, and in 4 of 46 (8.7%) patients with moderate coronavirus (p < 0.05). A decrease in total plasma testosterone levels occurred in 10 of 16 (62,5%) men of the severe disease group and in 4 of 46 (8.7%) men with moderate disease (p < 0.05).
CONCLUSIONS: Our findings demonstrate the negative impact of COVID-19 on male fertility and hormonal status. The coronavirus severity mainly determines the rate, intensity and duration of spermatogenesis disorders and hypogonadism manifestations that occur after it.
Keywords
Full Text

About the authors
Yuri A. Ignashov
Academician I.P. Pavlov First St. Petersburg State Medical University
Author for correspondence.
Email: yuri.ignashov@gmail.com
ORCID iD: 0000-0003-0773-0711
SPIN-code: 2243-0734
MD, Cand. Sci. (Medicine)
Russian Federation, Saint PetersburgSergey Yu. Borovets
Academician I.P. Pavlov First St. Petersburg State Medical University
Email: sborovets@mail.ru
ORCID iD: 0000-0003-2162-6291
SPIN-code: 2482-0230
MD, Dr. Sci. (Medicine), Professor
Russian Federation, Saint PetersburgMaxim A. Rybalov
Academician I.P. Pavlov First St. Petersburg State Medical University
Email: maxrybalov@mail.ru
ORCID iD: 0000-0001-8951-5315
SPIN-code: 4498-7970
MD, Cand. Sci. (Medicine)
Russian Federation, Saint PetersburgMaria K. Potapova
Academician I.P. Pavlov First St. Petersburg State Medical University
Email: maria.potapova.92@mail.ru
ORCID iD: 0000-0002-0288-9777
SPIN-code: 5235-3154
MD, Cand. Sci. (Medicine)
Russian Federation, Saint PetersburgSalman Kh. Al-Shukri
Academician I.P. Pavlov First St. Petersburg State Medical University
Email: alshukri@mail.ru
ORCID iD: 0000-0002-4857-0542
SPIN-code: 2041-8837
Scopus Author ID: 6601962854
MD, Dr. Sci. (Medicine), Professor
Russian Federation, Saint PetersburgReferences
- www.who.int [Internet]. Novel coronavirus (2019-nCoV). Situation report-1. WHO bulletin. January 21, 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn= 20a99c10_4
- Harapan H, Itoh N, Yufika A, et al. Coronavirus disease 2019 (COVID-19): a literature review. J Infect Public Health. 2020;13(5): 667–673. doi: 10.1016/j.jiph.2020.03.019
- Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. doi: 10.1016/S2213-2600(20)30076-X
- Giri M, Puri A, Wang T, Guo S. Comparison of clinical manifestations, pre-existing comorbidities, complications and treatment modalities in severe and non-severe COVID-19 patients: A systemic review and meta-analysis. Sci Prog. 2021;104(1):368504211000906. doi: 10.1177/00368504211000906
- Howell CR, Zhang L, Yi N, et al. Associations between cardiometabolic disease severity, social determinants of health (SDoH) and poor COVID-19 outcomes. Obesity (Silver Spring). 2022;30(7): 1483–1494. doi: 10.1002/oby.23440
- Pijls BG, Jolani S, Atherley A, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ open. 2021;11(1):e044640. doi: 10.1136/bmjopen-2020-044640
- Vahedian-Azimi A, Pourhoseingholi MA, Saberi M, et al. Gender susceptibility to COVID-19 mortality: Androgens as the usual suspects? In: Guest PC, editor. Clinical, biological and molecular aspects of COVID-19. Advances in experimental medicine and biology. Vol. 1321. Springer, Cham; 2021. P. 261–264. doi: 10.1007/978-3-030-59261-5_23
- Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8. doi: 10.1016/j.cell.2020.02.052
- Parmar MS. TMPRSS2: An equally important protease as ACE2 in the pathogenicity of SARS-CoV-2 infection. Mayo Clin Proceed. 2021;96(11):2748–2752. doi: 10.1016/j.mayocp.2021.07.005
- Wan Z, Xu X. scRNA-seq profiling of human testes reveals the presence of the ACE2 receptor, a target for SARS-CoV-2 infection in spermatogonia, leydig and sertoli cells. Cells. 2020;9(4):920. doi: 10.3390/cells9040920
- Li D, Jin M, Bao P, et al. Clinical characteristics and results of semen tests among men with coronavirus disease 2019. JAMA Netw Open. 2020;3(5):e208292. doi: 10.1001/jamanetworkopen.2020.8292
- Pan F, Xiao X, Guo J, et al. No evidence of SARS-CoV-2 in semen of males recovering from COVID-19. Fertil Steril. 2020;113(6): 1135–139. doi: 10.1016/j.fertnstert2020.04.024
- Song C, Wang Y, Li W, et al. Absence of 2019 novel coronavirus in semen and testis of COVID-19 patients. Biol Reprod. 2020;103(1):4–6. doi: 10.1093/biolre/ioaa050
- Xu J, Qi L, Chi X, et al. Orchitis: a complication of severe acute respiratory syndrome (SARS). Biol Reprod. 2006;74(2):410–416. doi: 10.1095/biolreprod.105.044776
- Liu W, Han R, Wu H, Han D. Viral threat to male fertility. Andrologia. 2018;50(11):e13140. doi: 10.1111/and.13140
- Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323(18):1843–1844. doi: 10.1001/jama.2020.3786
- Lardone MC, Piottante A, Valdevenito R, et al. Histological and hormonal testicular function in oligo/azoospermic infertile men. Andrologia. 2013;45(6):379–385. doi: 10.1111/and.12026
- Moore BJB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473–474. doi: 10.1126/science.abb8925
- Frasca D, Blomberg BB. Inflammaging decreases adaptive and innate immune responses in mice and humans. Biogerontology. 2016;17(1):7–19. doi: 10.1007/s10522-015-9578-8
- Temiz MZ, Dincer MM, Hacibey I, et al. Investigation of SARS-CoV-2 in semen samples and the effects of COVID-19 on male sexual health by using semen analysis and serum male hormone profile: A cross-sectional, pilot study. Andrologia. 2020;53(2):e13912. doi: 10.1111/and.13912
- Falahieh FM, Zarabadipour M, Mirani M, et al. Effects of moderate COVID-19 infection on semen oxidative status and parameters 14 and 120 days after diagnosis. Reprod Fertil Dev. 2021;33(12):683–690. doi: 10.1071/rd21153
- Gacci M, Coppi M, Baldi E, et al. Semen impairment and occurrence of SARS-CoV-2 virus in semen after recovery from COVID-19. Hum Reprod. 2021;36(6):1520–1529. doi: 10.1093/humrep/deab026
- Dashko AA, Elagin VV, Kiseleva YuYu, et al. Impact of COVID-19 and other viral infections of male fertility (preliminary data). Russian Journal of Human Reproduction. 2020;26(6):8388. EDN: PHIPYS doi: 10.17116/repro20202606183
- Enikeev D, Taratkin M, Morozov A, et al. Prospective two-arm study of the testicular function in patients with COVID-19. Andrology. 2022;10(6):1047–1056. doi: 10.1111/andr.13159
Supplementary files
